TMCIglobenewswire

Treace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2025 Revenue

Summary

PONTE VEDRA, Fla., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced its preliminary, unaudited fourth quarter and full-year 2025 revenue results.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on January 13, 2026 by globenewswire

    Treace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2025 Revenue | TMCI Stock News | Candlesense